Journal ArticleOPEN ACCESS

Esketamine nasal spray for treatment‐resistant depression

  • Chaplin S
Prescriber (2020) 31(5) 32-34
DOI: 10.1002/psb.1845
N/ACitations
Citations of this article
12Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

A nasal spray formulation of esketamine (Spravato) was licensed as adjunctive therapy for the management of adults with treatment‐resistant major depression in December. This article discusses the properties, clinical trial efficacy and adverse effects of this new treatment option.

Cite

CITATION STYLE

APA

Chaplin, S. (2020). Esketamine nasal spray for treatment‐resistant depression. Prescriber, 31(5), 32–34. https://doi.org/10.1002/psb.1845

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free